181 Background: Neoadjuvant pembrolizumab at 200 mg in combination with high dose
IFNα2b (HDI) for locally/regionally advanced or recurrent melanoma may improve the …

The global incidence of malignant melanoma, the leading cause of skin cancer death, has
steadily increased in recent years. Surgical excision is the treatment of choice for early-stage …

Surgery still is the cornerstone of treatment for patients with stage II and III melanoma, but
despite great efforts to gain or preserve locoregional control with excision of the primary …

The standard of care for patients with resectable stage III/IV melanoma classically included
upfront resection with adjuvant therapy. However, in more recent years, the amount of …

Introduction Locoregionally advanced melanoma represents a large group of high-risk
melanoma patients at presentation and poses major challenges in relation to management …

TPS9605 Background: Adjuvant (adj) immune checkpoint inhibition (ICI) improves relapse
free survival (RFS) in stage III melanoma patients (pts). However, preclinical and …

Background SEMA4D has broad immunomodulatory effects in the tumor microenvironment;
blocking SEMA4D in combination with checkpoint inhibitors (CI) promotes immune …

Background Before adjuvant checkpoint inhibition the 5-year overall survival (OS) rate was
poor (< 50%) in high-risk stage III melanoma patients. Adjuvant CTLA-4 (ipilimumab, IPI) and …

Patients with resected stage IIB/C melanoma have high recurrence risk, similar to those with
resected stage IIIA/B disease. The phase 3, double-blind CheckMate 76K trial assessed 790 …

Background Patients with stage IIB or IIC melanoma who undergo surgery alone are at a
substantial risk for disease recurrence. Adjuvant pembrolizumab significantly improved …